Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06285097 · ClinicalTrials.gov registry record · Phase 1
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT06285097: Clinical Trial Phase 1 study, sponsored by Pfizer.
NCT06285097 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06285097, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study aims to evaluate the safety, and early signals of anti-tumor activity of PF-07820435 when administered alone (Part 1A) or in combination with sasanlimab (Part 1B; Part 2) in patients with selected advanced or metastatic solid tumors. Part 1 will be dose-finding and Part 2 of the study will further evaluate PF-07820435 at the recommended dose for combination expansion in patients with selected advanced solid tumors.
Primary Outcome
DLT rate estimated based on data from DLT-evaluable participants during the DLT evaluation period
Interventions
- BIOLOGICAL Sasanlimab
- DRUG PF-07820435
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2024-02-08 |
| Est. Completion | 2025-02-13 |
| Phase | Phase 1 |
Why NCT06285097 stopped before completion
NCT06285097 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Sasanlimab is the first listed.
NCT06285097 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06285097 about?
NCT06285097 is a clinical study titled "A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors". This study aims to evaluate the safety, and early signals of anti-tumor activity of PF-07820435 when administered alone (Part 1A) or in combination with sasanlimab (Part 1B; Part 2) in patients with selected advanced or metastatic solid tumors. Part 1 will be dose-finding and Part 2 of the study wil...
What is the current status of trial NCT06285097?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2024-02-08. Estimated completion is 2025-02-13.
What interventions are being tested in trial NCT06285097?
The interventions under investigation include: Sasanlimab (BIOLOGICAL), PF-07820435 (DRUG).
Who is sponsoring clinical trial NCT06285097?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06285097's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI